Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial

CONCLUSION: Nivolumab maintenance following platinum-based chemotherapy did not show clinical benefits after EGFR-TKI failure in patients with EGFR-mutant NSCLC.PMID:37699785 | DOI:10.1111/1759-7714.15083

Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Jiwon Kim Chang-Min Choi Wonjun Ji Jae Cheol Lee Source Type: research